non-structural protein 5 [SARS-CoV-2]

Overview

Non-structural protein 5 (nsp5) of SARS-CoV-2, widely known as the main protease (M^pro) or 3C-like protease (3CL^pro), is a cysteine protease encoded within the viral genome that plays an indispensable role in the coronavirus replication cycle. Upon translation of the viral polyprotein, M^pro acts as the primary processing enzyme, cleaving the large polyprotein precursors (pp1a and pp1ab) at no fewer than 11 conserved sites to release the individual functional non-structural proteins required for genome replication and transcription. The active enzyme functions as a homodimer, with each protomer contributing a catalytic dyad composed of a nucleophilic cysteine (Cys145) and a histidine residue (His41) that together orchestrate peptide bond hydrolysis through a well-characterized thiolate-imidazolium ion pair mechanism.

M^pro is widely regarded as one of the most compelling antiviral drug targets to emerge from the COVID-19 pandemic. Its substrate cleavage specificity — preferring glutamine in the P1 position — differs markedly from mammalian proteases, and the enzyme lacks a closely related human homologue, substantially reducing the likelihood of on-target toxicity. These properties made it the molecular target of nirmatrelvir, the active covalent inhibitor component of nirmatrelvir/ritonavir (Paxlovid), the first orally administered protease inhibitor approved for COVID-19. The structural accessibility of M^pro's active site, combined with the accumulation of high-resolution crystallographic data, has catalyzed sustained medicinal chemistry campaigns aimed at developing next-generation inhibitors with improved potency, selectivity, and pharmacokinetic profiles.

Focus of Latest Publications

Recent research on non-structural protein 5 (the main protease, Mpro) of SARS-CoV-2 has centered on developing novel small-molecule inhibitors as alternatives to the current standard-of-care treatment, nirmatrelvir/ritonavir (Paxlovid), which is associated with adverse effects and drug-drug interactions. The catalytic role of Mpro in viral genome replication and its conservation across coronaviruses make it an attractive antiviral target, particularly given the continued evolution of SARS-CoV-2 driven by the virus's lack of proofreading capacity during replication.

Structure-based drug discovery approaches have dominated recent efforts, employing computational and experimental screening to identify inhibitor scaffolds. Virtual screening campaigns have yielded several promising hit series, including spiropyrrolidinoxindole derivatives with low-micromolar inhibitory activity and novel 3-phenyl-2H-aziridine heterocyclic derivatives, with the most potent compound (3ab) achieving an IC50 of 0.41 μM as a covalent irreversible inhibitor. Fragment-based design has also proven productive, with linked fragments derived from a high-throughput crystallographic screen yielding single-digit micromolar covalent inhibitors, though success in this approach has been heavily dependent on factors including warhead type, linker design, and induced-fit effects. Machine learning approaches, including target-specific deep learning workflows and random forest models trained on diverse structural data, have accelerated candidate prioritization and identification; one deep learning approach identified a novel covalent inhibitor fragment with an IC50 of 1.5 μM that uniquely engages the S3′ pocket of Mpro.

Most identified inhibitors function through covalent modification of the catalytic cysteine residue Cys145, with detailed structural studies revealing distinct binding mechanisms. While many inhibitors rely heavily on this covalent interaction with supporting van der Waals contacts, others form extensive hydrogen-bonding networks. Notably, a unique N,N-diaryl-α,α-dichloroacetamide scaffold was discovered to exhibit dual covalent reactivity, forming bonds to both Cys145 and the catalytic histidine (His41) in some cases, suggesting a novel strategy for simultaneous inhibition. Beyond traditional covalent inhibitors, targeted protein degradation has emerged as an alternative therapeutic modality; a VHL-addressing PROTAC derived from an Mpro inhibitor scaffold achieved effective degradation of Mpro in SARS-CoV-2-infected cells with a DC50 of 0.9 μM and demonstrated antiviral activity in the low micromolar range in both standard and physiologically relevant human lung cell models.